Gilead Targets HIV Prevention Dominance With Twice-Yearly Yeztugo as GSK Mounts a Defense Gilead Sciences is taking a bold step to further entrench itself as the dominant force in HIV care, this time with its latest innovation in pre-exposure prophylaxis…
Merck Finalizes $3.4 Billion Acquisition of SpringWorks Therapeutics to Strengthen Rare Tumor Portfolio and Drive Sustainable Healthcare Growth Merck, a global leader in science and technology, today announced the successful completion of its acquisition of SpringWorks Therapeutics, Inc. for an…
CVS Health Launches Workforce Innovation and Talent Center in Chicago to Strengthen Community Employment and Training Opportunities In a significant step toward fostering economic opportunity and addressing workforce gaps, CVS Health has officially launched its newest Workforce Innovation and Talent…
Royalty Pharma and Revolution Medicines Forge $2 Billion Strategic Funding Pact to Accelerate Global Development of RAS Cancer Therapies Royalty Pharma plc, a prominent funder of innovation in the biopharmaceutical industry, announced a transformative agreement with Revolution Medicines, Inc., securing…
Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership. Extending their 16-year collaboration…
BioNTech and Bristol Myers Squibb Forge $11.1 Billion Global Partnership to Advance Bispecific Cancer Antibody BNT327 Across Multiple Solid Tumor Types In a move that signals a major step forward in the fight against some of the most challenging forms…
AbbVie and ADARx Partner to Advance Next-Generation siRNA Therapies Across Neuroscience, Immunology, and Oncology in Multibillion-Dollar Collaboration AbbVie, a global biopharmaceutical leader known for its portfolio of therapies in immunology, oncology, neuroscience, and other specialty areas, has announced a significant…
Innate Pharma Announces First Quarter 2025 Financial Results and Business Highlights Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage oncology-focused biotechnology company pioneering innovative immunotherapies, announced its consolidated financial results for the first quarter ending March 31, 2025,…
Eli Lilly and Purdue University Announce Landmark $250 Million Research Collaboration Eli Lilly and Company (NYSE: LLY) and Purdue University today unveiled a major expansion of their long-standing partnership, with Lilly committing up to $250 million over the next eight…
Merck Animal Health and State of Kansas Announce $895 Million Investment in De Soto Manufacturing and R&D Facilities Merck Animal Health launches its largest economic development project to date Rahway, NJ, May 8, 2025 — Merck Animal Health, known as…
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving the lives of people with severe autoimmune diseases, today announced its financial results for the first quarter of 2025 and provided a comprehensive business update. CEO Statement…
Strong FY2024 Performance and Strategic Outlook for FY2025 The company reported core revenue growth of 7.4% at actual exchange rates (AER) and 2.8% at constant exchange rates (CER) for fiscal year 2024, reflecting solid product performance across key markets. Core…